Go to main content
Back to to isofolmedical.com
SV EN

News Published

"Encouraging to see the efficacy signals sustained at the highest dose level"

Isofol's Chief Medical Officer Roger Tell discusses the preliminary results from the ongoing phase Ib/II study.

Video

More news

Cookies

We value your privacy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Read our Cookie policy.